The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)
About this episode
On our Novo Nordisk episode, we covered the business of Ozempic, the GLP-1 taking the world by storm. On this episode, we dive into the science of the molecule semaglutide (and its predecessor liraglutide) with the world expert on the topic, Lotte Bjerre Knudsen. Lotte is Novo Nordisk’s Chief Scientific Advisor, and led the research group back in the early 1990s that first invented the molecule. A few topics from our conversation:
- The science behind what is happening in the body that causes weight loss while on Ozempic
- What it was like in the 1990s and 2000s believing in a drug for a problem that the rest of the industry (including her own company) had written off
- How weight loss was actually a goal from the very start — not just a side effect of diabetes medication like you often read today!
Sponsors:
- Sierra: https://bit.ly/acquiredsierra
Get every episode summarized
Each time ACQ2 by Acquired publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from ACQ2 by Acquired
The Insane Productivity of Andrew Ross Sorkin
ACQ2 by Acquired
How to Live in Everyone Else's Future (with Shopify CEO Tobi Lütke)
ACQ2 by Acquired
How is AI Different Than Other Technology Waves? (With Bret Taylor and Clay Bavo...
ACQ2 by Acquired
Building the Savannah Bananas (with Jesse Cole, Founder and Owner)
ACQ2 by Acquired